Can Takeda Help Deliver Shire's China Rare Disease Dream?
Executive Summary
Coming out of the local integration with Baxter's spin-off Baxalta in China, Shire may have to face more uncertainties in the country despite erstwhile acquirer Takeda having a much larger presence there, while competition is also brewing for the merged company from rare disease heavyweights such as Roche and Biogen.
You may also be interested in...
Multinationals Score Three Out Four New China Priority Reviews
Eight drugs from foreign multinationals, including Amgen’s Rapatha, Takeda’s Takecab, Sanofi’s Aubagio and UCB’s Cimzia, are among 12 products awarded priority new drug approval reviews in China under a scheme to speed up approvals and patient access that is also benefiting some domestic players.
Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina
Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.